Key result
NT-proBNP changes are not associated with LVEF reduction after anthracycline chemotherapy in breast cancer.
Why the study?
Decreased LVEF is less sensitive for detecting subclinical anthracycline-induced cardiotoxicity in breast cancer patients, and previous studies evaluating NT-proBNP as an alternative biomarker have yielded varied results.
Does change in NT-proBNP level correlate with change in left ventricular ejection fraction in female breast cancer patients completing anthracycline-based chemotherapy?
Cross-Sectional (n=47)
No
Does change in NT-proBNP level correlate with change in left ventricular ejection fraction in female breast cancer patients completing anthracycline-based chemotherapy?
Short-term changes in NT-proBNP levels measured 1-4 weeks after completing anthracycline-based chemotherapy did not significantly correlate with early reductions in LVEF in breast cancer patients.
Answers are grounded in this paper and cite their sources.
NT-proBNP changes were not associated with LVEF reduction; leaves open biomarker utility for anthracycline cardiotoxicity surveillance in breast cancer.
Background. Anthracycline-based breast cancer chemotherapy has a toxic effect on the heart or cardiotoxicity that affects the survival of breast cancer patients. Decreased LVEF is less sensitive for detecting subclinical cardiotoxicity. NT-proBNP is known as a biomarker of heart failure, currently being widely studied as an alternative to assess the toxic effects of anthracyclines on the heart but the results are still varied. This study aim to assess the association between changes in NT-proBNP levels and LVEF value in breast cancer patients after completing anthracycline-based chemotherapy at Dr. Sardjito hospitalMethods. A cross-sectional observational study was conducted in May - November 2022. Data was taken from the clinical registry and medical records of breast cancer patients diagnosed from 2018 - 2020 who met the inclusion and exclusion criteria. Sampling was done with consecutive sampling method. The association between changes in NT-proBNP levels and LVEF was analyzed using Pearson's correlation test if the data were normally distributed, or Spearman's correlation test if the data were not normally distributed.Results. There were 47 breast cancer patients with an average age of 52.74 ± 8.30 years old. There was a significant decrease in LFEV before and after the completion of chemotherapy (71.17 ± 5.98 % to 68.72 ± 6.77 %, p=0.003). Meanwhile, NT-proBNP levels did not increase significantly after chemotherapy (65.80 (10.00 – 483.6) pg/mL to 70.70 (9.30 – 1370) pg/mL, p=0.452). There was a weak but not significant negative association between changes in NT-proBNP levels and decreased LVEF after the completion of anthracycline-based chemotherapy (r = -0.186, p = 0.211). Other factors such as age, cumulative dose of anthracyclines, diabetes mellitus, hypertension, clinical stage of cancer, body mass index, and combination chemotherapy with taxane were also not significantly associated with the decrease in LVEF after chemotherapy.Conclusion. No significant association was found between changes in NT-proBNP levels and a decrease in LVEF measured after the completion of anthracycline-based chemotherapy in breast cancer patients at Dr. Sardjito hospital.
No takes yet. Share an insight, caveat, or question.
Fatmawati et al. (2026) conducted a cross-sectional in Breast cancer receiving anthracycline-based chemotherapy (n=47). Changes in NT-proBNP levels after anthracycline-based chemotherapy was evaluated on Correlation between changes in NT-proBNP levels and changes in LVEF after anthracycline-based chemotherapy (r = -0.148, p=0.322). Changes in NT-proBNP levels were not significantly associated with LVEF reduction after anthracycline-based chemotherapy in breast cancer patients (r = -0.148, p = 0.322).
Synapse has enriched 10 related papers. Consider them for comparative context: